These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 15462112)

  • 1. Association between activated renin angiotensin system and bone formation in hemodialysis patients: is the bone mass genetically determined by ACE gene polymorphism?
    Altun B; Kiykim AA; Seyrantepe V; Usalan C; Arici M; Cağlar M; Erdem Y; Yasavul U; Turgan C; Cağlar S
    Ren Fail; 2004 Jul; 26(4):425-31. PubMed ID: 15462112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TNF alpha-308 genotype and renin-angiotensin system in hemodialysis patients: an effect on inflammatory cytokine levels?
    Genctoy G; Altun B; Kiykim AA; Arici M; Erdem Y; Cağlarg M; Yasavul U; Turgan C; Cağlar S
    Artif Organs; 2005 Feb; 29(2):174-8. PubMed ID: 15670287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship Between Angiotensin-converting Enzyme Gene Polymorphism and QT Dispersion in Hemodialysis Patients.
    Toraman A; Colak H; Tekce H; Cam S; Kursat S
    Iran J Kidney Dis; 2017 May; 11(3):217-222. PubMed ID: 28575882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiotensin-converting enzyme gene polymorphism has no influence on the circulating renin-angiotensin-aldosterone system or blood pressure in normotensive subjects.
    Lachurié ML; Azizi M; Guyene TT; Alhenc-Gelas F; Ménard J
    Circulation; 1995 Jun; 91(12):2933-42. PubMed ID: 7796503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renin-angiotensin polymorphisms and QTc interval prolongation in end-stage renal disease.
    Raizada V; Skipper B; Luo W; Garza L; Hines CW; Harford AA; Zager PG; Griffith J; Raj D; Spalding CT
    Kidney Int; 2005 Sep; 68(3):1186-9. PubMed ID: 16105049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced plasma levels of angiotensin-(1-7) and renin activity in preeclamptic patients are associated with the angiotensin I- converting enzyme deletion/deletion genotype.
    Velloso EP; Vieira R; Cabral AC; Kalapothakis E; Santos RA
    Braz J Med Biol Res; 2007 Apr; 40(4):583-90. PubMed ID: 17401503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical usefulness of the serum N-terminal propeptide of type I collagen as a marker of bone formation in hemodialysis patients.
    Ueda M; Inaba M; Okuno S; Nagasue K; Kitatani K; Ishimura E; Shimizu M; Miki T; Kim M; Nishizawa Y
    Am J Kidney Dis; 2002 Oct; 40(4):802-9. PubMed ID: 12324916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High prevalence of ACE DD genotype among north Indian end stage renal disease patients.
    Tripathi G; Dharmani P; Khan F; Sharma RK; Pandirikkal V; Agrawal S
    BMC Nephrol; 2006 Oct; 7():15. PubMed ID: 17042963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between ACE and AGT polymorphism and cardiovascular risk in acromegalic patients.
    Erbas T; Cinar N; Dagdelen S; Gedik A; Yorgun H; Canpolat U; Kabakci G; Alikasifoglu M
    Pituitary; 2017 Oct; 20(5):569-577. PubMed ID: 28712073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Arteriovenous fistula patency associated with angiotensin-converting enzyme I/D polymorphism and ACE inhibition or AT1 receptor blockade.
    Moon JY; Jeong KH; Paik SS; Han JJ; Lee SH; Lee TW; Ihm CG; Kim MJ; Chung JH
    Nephron Clin Pract; 2009; 111(2):c110-6. PubMed ID: 19142023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polymorphism of the angiotensin-converting enzyme gene in end-stage renal failure patients.
    Aucella F; Vigilante M; Margaglione M; Grandone E; del Popolo A; Forcella M; Procaccini D; Salatino G; Passione A; Ktena M; De Min A; Stallone C
    Nephron; 2000 May; 85(1):54-9. PubMed ID: 10773756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is AV fistula patency associated with angiotensin-converting enzyme (ACE) polymorphism and ACE inhibitor intake?
    Heine GH; Ulrich C; Köhler H; Girndt M
    Am J Nephrol; 2004; 24(4):461-8. PubMed ID: 15331890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of 12 months of recombinant growth hormone therapy on parameters of bone metabolism and bone mineral density in patients on chronic hemodialysis.
    Kotzmann H; Riedl M; Pietschmann P; Schmidt A; Schuster E; Kreuzer S; Kainberger F; Frisch H; Geyer G; Hörl WH; Mayer G; Luger A
    J Nephrol; 2004; 17(1):87-94. PubMed ID: 15151263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiotensin-converting enzyme (ACE) insertion/deletion polymorphism and survival in a cohort of chronic hemodialysis patients.
    Higashiuesato Y; Tana T; Tozawa M; Iseki C; Iseki K; Fukiyama K; Takishita S
    Clin Nephrol; 2002 Nov; 58(5):370-5. PubMed ID: 12425488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum angiotensin-converting enzyme 2 concentration and angiotensin-(1-7) concentration in patients with acute heart failure patients requiring emergency hospitalization.
    Hisatake S; Kiuchi S; Kabuki T; Oka T; Dobashi S; Ikeda T
    Heart Vessels; 2017 Mar; 32(3):303-308. PubMed ID: 27421979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response of serum angiotensin converting enzyme, plasma renin activity and plasma aldosterone to conventional dialysis in patients on chronic haemodialysis.
    Letizia C; Mazzaferro S; Morabito S; De Ciocchis A; Cerci S; D'Ambrosio C; Cinotti GA; Scavo D
    Int Urol Nephrol; 1995; 27(4):465-70. PubMed ID: 8586522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiotensin-converting enzyme gene polymorphism and vascular manifestations in Korean patients with SLE.
    Uhm WS; Lee HS; Chung YH; Kim TH; Bae SC; Joo KB; Kim TY; Yoo DH
    Lupus; 2002; 11(4):227-33. PubMed ID: 12043886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone mineral density and biochemical markers of bone turnover in patients with predialysis chronic renal failure.
    Rix M; Andreassen H; Eskildsen P; Langdahl B; Olgaard K
    Kidney Int; 1999 Sep; 56(3):1084-93. PubMed ID: 10469378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum levels of C-terminal telopeptide of type I collagen: a useful new marker of cortical bone loss in hemodialysis patients.
    Okuno S; Inaba M; Kitatani K; Ishimura E; Yamakawa T; Nishizawa Y
    Osteoporos Int; 2005 May; 16(5):501-9. PubMed ID: 15309383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. No association between deletion-type angiotensin-converting enzyme gene polymorphism and left-ventricular hypertrophy in hemodialysis patients.
    Yildiz A; Akkaya V; Hatemi AC; Cine N; Tükek T; Görçin B; Demirel S; Türk S; Sever MS
    Nephron; 2000 Feb; 84(2):130-5. PubMed ID: 10657713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.